51�ؿ�����

In brief:

• Facts about the study: peer-reviewed // basic research // translational research // in vivo // in vitro //
• The study shows how a newly discovered mechanism helps leukemia cells to evade the immune system.
• By generating a new antibody, the researchers could impede the mechanism and the immune system regained the ability to identify and combat the cancer cells.
• The studies involving the antibody are conducted on, among other things, human cells that are transplanted into mice.

Immunotherapy has improved the treatment for many cancers, but progress has been limited in leukemia. Acute myeloid leukemia (AML) is particularly intractable, with a five-year survival rate of just over 30 per cent. The existing treatments are often aggressive and may include both strong chemotherapy and stem cell transplantations.

“We wanted to see if we could find surface proteins unique to leukemia stem cells, and which would therefore act as interesting targets for a targeted treatment. If such proteins were not present on healthy blood stem cells it might be possible to attack the tumour – without harming the healthy blood system,” says Thoas Fioretos, research group leader and professor of clinical genetics at 51�ؿ�����, and senior consultant at Skåne University Hospital.

When we blocked the surface protein, using a specific antibody we developed in cooperation with the SciLifeLab Drug Discovery and Development Platform, the T cells could suddenly detect and kill the cancer cells – both in test tubes and in mice.

In the new study, the researchers identified a previously unknown surface protein that is expressed on the leukemia stem cells, but not on healthy blood stem cells. The discovery was enabled by a large-scale mapping of proteins in leukemia stem cells in bone marrow samples from three patients with particularly intractable AML. The mapping was then compared with the blood stem cells of healthy individuals. It was then that the researchers discovered the surface protein, SLAMF6, was only expressed on the diseased cells. The finding was then validated in an additional 50 AML patients.

The researchers then studied the protein’s function in CRISPR/Cas9 gene scissors experiments. The protein was shown to play a central role in how the cancer cells evade detection by the immune system’s T cells, which means that the cancer cells can continue to grow undisturbed.

It was also shown that the mechanism can be attacked.

“When we blocked the surface protein, using a specific antibody we developed in cooperation with the SciLifeLab Drug Discovery and Development Platform, the T cells could suddenly detect and kill the cancer cells – both in test tubes and in mice,” says Carl Sandén, researcher at 51�ؿ�����. He and Thoas Fioretos are the corresponding authors of the study.

It was like turning on the switch to the immune system again. When the surface protein does its job, it helps the cancer cell to elude the immune system, but by turning it off with the developed antibody, the immune system’s T cells could attack and kill the cancer cells.

“Our discovery can partially explain why immunotherapies have thus far only had a limited effects in AML. It’s an important step forward, but continued research and clinical trials will be needed before it can be relevant as a treatment for a patient group that is in great need of new therapies,” says Niklas Landberg, research group leader at 51�ؿ����� and medical registrar in hematology at Skåne University Hospital, and one of the researchers behind the study.

The study marks a step towards more individualised cancer therapy, in which the patient’s tumour can be attacked based on its unique characteristics and defences. The work on further development and testing of the antibody will continue, with an aim to establish future clinical trials.

The team behind the study has started a spin-off company, Lead Biologics, which is now driving the commercial development of the antibody as a future medicine.